Administration of a gonadotropin-releasing hormone agonist during pregnancy: follow-up of 28 pregnancies exposed to triptoreline.
To evaluate the teratogenic or fetal risk of a long-acting GnRH agonist (GnRH-a) triptoreline acetate (Decapeptyl; Ipsen-Biotech, Inc., Paris, France), inadvertently administrated in the first weeks of pregnancy. Prospective follow-up of exposed pregnancies and case reports. Teratology information service of a public hospital and pharmacovigilance department of the firm. Inadvertent pregnant women receiving a treatment, mainly for endometriosis or IVF. Case by case, individual estimations of the risks have been provided. Each pregnancy issue has been analyzed. No teratogenic or fetal toxic effect has been noted. No specific hazard has been observed among newborns after inadvertent exposures to a GnRH-a during the first 20 weeks of pregnancy.